At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...
New York, USA, July 10, 2025 (GLOBE NEWSWIRE) -- Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight ...
Canakinumab shows superior efficacy and safety over anakinra in male patients with VEXAS syndrome, a multicenter study finds.
New York, March 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Interleukin Inhibitors Global Market Report 2022" - https://www ...
Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine that regulates T-cell and natural killer-cell responses, induces the production of interferon-γ (IFN-γ), favours the differentiation ...
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival Eleven ...
Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...
The impact of IL10 mutation in birds highlights the intrinsic compromise between effective elimination of a pathogen and damage to the host.
A pleiotropic cytokine central to the regulation of T-cell responses, interleukin 2 (IL-2), plays an essential role in a huge range of other immune modulatory actions. Image Credit: Sino Biological ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback